JP6961625B2 - 抗ｔｎｆｒｓｆ２５抗体 - Google Patents

抗ｔｎｆｒｓｆ２５抗体 Download PDF

Info

Publication number
JP6961625B2
JP6961625B2 JP2018563618A JP2018563618A JP6961625B2 JP 6961625 B2 JP6961625 B2 JP 6961625B2 JP 2018563618 A JP2018563618 A JP 2018563618A JP 2018563618 A JP2018563618 A JP 2018563618A JP 6961625 B2 JP6961625 B2 JP 6961625B2
Authority
JP
Japan
Prior art keywords
antibody
tnfrsf25
seq
composition
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018563618A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019526528A5 (OSRAM
JP2019526528A (ja
Inventor
エイチ． シュライバー，テイラー
ティー． ハッチンス，ジェフ
Original Assignee
ペリカン セラピューティクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ペリカン セラピューティクス，インコーポレイテッド filed Critical ペリカン セラピューティクス，インコーポレイテッド
Publication of JP2019526528A publication Critical patent/JP2019526528A/ja
Publication of JP2019526528A5 publication Critical patent/JP2019526528A5/ja
Application granted granted Critical
Publication of JP6961625B2 publication Critical patent/JP6961625B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018563618A 2016-06-09 2017-06-09 抗ｔｎｆｒｓｆ２５抗体 Expired - Fee Related JP6961625B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662348009P 2016-06-09 2016-06-09
US62/348,009 2016-06-09
PCT/US2017/036817 WO2017214547A1 (en) 2016-06-09 2017-06-09 Anti-tnfrsf25 antibodies

Publications (3)

Publication Number Publication Date
JP2019526528A JP2019526528A (ja) 2019-09-19
JP2019526528A5 JP2019526528A5 (OSRAM) 2020-07-16
JP6961625B2 true JP6961625B2 (ja) 2021-11-10

Family

ID=59078259

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018563618A Expired - Fee Related JP6961625B2 (ja) 2016-06-09 2017-06-09 抗ｔｎｆｒｓｆ２５抗体

Country Status (15)

Country Link
US (3) US10005843B2 (OSRAM)
EP (1) EP3468998B1 (OSRAM)
JP (1) JP6961625B2 (OSRAM)
KR (1) KR102423942B1 (OSRAM)
CN (1) CN109219620B (OSRAM)
AU (1) AU2017278192A1 (OSRAM)
BR (1) BR112018075222A2 (OSRAM)
CA (1) CA3026652A1 (OSRAM)
DK (1) DK3468998T3 (OSRAM)
IL (1) IL263406B2 (OSRAM)
MX (1) MX389320B (OSRAM)
RU (1) RU2746314C2 (OSRAM)
SG (1) SG11201810853UA (OSRAM)
WO (1) WO2017214547A1 (OSRAM)
ZA (1) ZA201808317B (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014007426B1 (pt) 2011-09-30 2023-01-03 Teva Pharmaceuticals Australia Pty Ltd Anticorpos contra tl1a e seus usos
BR112017016681A2 (pt) * 2015-02-06 2018-04-10 Heat Biologics Inc vetor de coexpressão de vacina e moléculas coestimulatórias
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
AU2020340372A1 (en) * 2019-08-30 2022-03-10 Pelican Therapeutics, Inc. Methods of treating cancer using TNFRSF25 antibodies
WO2021062371A1 (en) * 2019-09-26 2021-04-01 Pelican Therapeutics, Inc. Tnfrsf25-mediated treatments of immune diseases and disorders
WO2022212668A1 (en) * 2021-03-31 2022-10-06 Heat Biologics, Inc. Methods and compositions related to tnfrsf25/dr3 agonists
WO2023244089A1 (ko) * 2022-06-17 2023-12-21 주식회사 셀렉신 인간 dr3에 특이적으로 결합하는 항체 및 이의 용도
CN120365425B (zh) * 2023-06-02 2025-12-16 安徽金百奥生物科技有限公司 一种靶向dr3胞外域的纳米抗体
GB202315963D0 (en) 2023-10-18 2023-11-29 Cancer Research Tech Ltd Binding molecules
US12319742B1 (en) 2024-01-24 2025-06-03 Shattuck Labs, Inc. Antibodies that bind TNFRSF25

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE247168T1 (de) 1991-03-06 2003-08-15 Merck Patent Gmbh Humanisierte monoklonale antikörper
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
GB9125979D0 (en) 1991-12-06 1992-02-05 Wellcome Found Antibody
EP0627002B1 (en) 1992-02-19 1998-09-23 Schering Corporation Cloning and expression of humanized monoclonal antibodies against human interleukin-4
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5705154A (en) 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
WO2005018571A2 (en) 2003-08-20 2005-03-03 University Of Miami Compositions and methods for treating inflammatory lung disease
US7612179B2 (en) 2003-11-28 2009-11-03 Astrazeneca Ab antibodies binding to a C-terminal fragment of apoliopoprotein E
JP5164167B2 (ja) 2005-08-30 2013-03-13 ユニバーシティー オブ マイアミ 免疫調節性腫瘍壊死因子受容体２５（ｔｎｆｒ２５）のアゴニスト、アンタゴニスト及び免疫毒素
SG10201608268RA (en) 2006-10-02 2016-11-29 Medarex Llc Human antibodies that bind cxcr4 and uses thereof
FR2907341B1 (fr) 2006-10-18 2012-08-17 Pf Medicament Utilisation d'un anticorps anti-cd151 pour le traitement du cancer
US20100092470A1 (en) 2008-09-22 2010-04-15 Icb International, Inc. Antibodies, analogs and uses thereof
DK2462165T3 (en) 2009-08-03 2016-08-29 Univ Miami Method for in vivo proliferation of regulatory T cells
WO2011106707A2 (en) * 2010-02-26 2011-09-01 Human Genome Sciences, Inc. Antibodies that specifically bind to dr3
GB201020995D0 (en) 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
JP2013040160A (ja) 2011-07-01 2013-02-28 Genentech Inc 自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用
EP2943253B1 (en) 2013-01-09 2021-10-20 University Of Miami Compositions and methods for the regulation of t regulatory cells using tl1a-ig fusion protein and il-2
RU2551235C2 (ru) * 2013-08-26 2015-05-20 Илья Владимирович Духовлинов Гуманизированное моноклональное антитело, специфичное к синдекану-1
CN103592439B (zh) * 2013-09-03 2015-10-21 天津亿美诺生物科技有限公司 人尿路上皮癌特异性抗体及其应用
US9982057B2 (en) * 2014-11-17 2018-05-29 Pelican Therapeutics, Inc. Human TNFRSF25 antibody

Also Published As

Publication number Publication date
US20170355773A1 (en) 2017-12-14
KR20190015716A (ko) 2019-02-14
WO2017214547A1 (en) 2017-12-14
KR102423942B1 (ko) 2022-07-22
US20210017287A1 (en) 2021-01-21
CA3026652A1 (en) 2017-12-14
BR112018075222A2 (pt) 2019-03-19
IL263406B2 (en) 2023-09-01
US10683359B2 (en) 2020-06-16
EP3468998A1 (en) 2019-04-17
MX389320B (es) 2025-03-20
US20180312599A1 (en) 2018-11-01
RU2018143977A (ru) 2020-07-09
AU2017278192A1 (en) 2018-12-13
RU2018143977A3 (OSRAM) 2020-10-05
RU2746314C2 (ru) 2021-04-12
CN109219620A (zh) 2019-01-15
IL263406A (en) 2018-12-31
EP3468998B1 (en) 2021-12-01
JP2019526528A (ja) 2019-09-19
IL263406B1 (en) 2023-05-01
SG11201810853UA (en) 2019-01-30
DK3468998T3 (en) 2022-03-07
ZA201808317B (en) 2019-08-28
CN109219620B (zh) 2023-01-31
US10005843B2 (en) 2018-06-26
MX2018014716A (es) 2019-03-11

Similar Documents

Publication Publication Date Title
JP6961625B2 (ja) 抗ｔｎｆｒｓｆ２５抗体
US12121579B2 (en) Antibodies specific to human t-cell immunoglobulin and ITIM domain (TIGIT)
JP2024088696A (ja) ヒトネクチン４に特異的な抗体
JP2020532965A (ja) 抗ｃｄ１３７分子及びその使用
US10683358B2 (en) Human TNFRSF25 antibody
JP2019516394A (ja) 新規抗ｐｄ−ｌ１抗体
WO2021093849A1 (en) A novel antibody against tigit
CN116710486A (zh) 用于治疗癌症的多特异性抗体
US20240270840A1 (en) Antibodies against cd112r and uses thereof
TW202413434A (zh) 以組合抗PD-1抗體之雙特異性抗PSMA x 抗CD28抗體治療轉移性去勢抗性前列腺癌之方法
CN116554325A (zh) 抗b7h3抗体及其应用
HK40007009B (en) Anti-tnfrsf25 antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200605

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200605

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210820

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210928

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211013

R150 Certificate of patent or registration of utility model

Ref document number: 6961625

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees